Basic Science
Funding
NIAID awards investigator-initiated research grants as well as grants and contracts in targeted areas addressed through various program solicitations (e.g., requests for applications/proposals, program announcements). Selected targeted programs include
This new grant program will support studies that are particularly innovative, novel, possibly high risk/high impact, and that have potential to advance understanding of the interactions of HIV proteins with cognate cellular binding partners. Awarded projects will have milestone "proof of concept" studies (R21), and then will be evaluated for the expanded development (R33) award without the need of submitting an additional grant application.
Co-funded by six NIH Institutes, including NIAID, the National Cancer Institute (NCI), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), the CFAR program provides administrative and shared research support to synergistically enhance and coordinate high-quality AIDS research projects. The CFAR program is scientifically managed by these six NIH Institutes as well as the National Center for Complementary and Alternative Medicine (NCCAM), the Office of AIDS Research (OAR), and the Fogarty International Center (FIC) of the National Institutes of Health (NIH).
CFARs accomplish this support through core facilities that provide expertise, resources, and services not otherwise readily obtained through more traditional funding mechanisms. The CFAR program emphasizes the importance of interdisciplinary collaboration, especially between basic and clinical investigators, translational research in which findings from the laboratory are brought to the clinic and vice versa, and an emphasis on inclusion of minorities and inclusion of prevention and behavioral change research.
There are currently 18 CFARs located at academic and research institutions throughout the United States.
This request for applications (RFA) seeks applications from single or consortia of institutions to participate in a cooperative, high-quality, focused, multidisciplinary pathogenesis research program in HIV-infected women. This research will enhance knowledge of the pathogenesis of HIV infection in women through investigations of biologic mechanisms that affect HIV transmission, disease acquisition, progression, and manifestations of HIV in women
The IPCP is a grant program that provides a continuous spectrum of research opportunities. IPCP supports research by collaborative groups seeking to transition from preclinical to clinical studies during the award period, as well as pilot clinical studies of novel treatments. This program is designed to promote creative and original therapeutic research on diverse facets of HIV infection between multidisciplinary preclinical and clinical research groups from academic or nonprofit institutions and research firms.
The HVDDT fund a focused team of scientists with development experience from industry and/or academia that have a mature, promising therapeutic vaccine concept and a plan for targeted development and clinical evaluation. The teams will advance the therapeutic vaccine concept along a well-defined development path in a timely manner toward product production and completion of a Phase I trial within the 5-year period of the contract. Applicants are encouraged, but not required, to conduct Phase I/II trials in collaboration with the NIAID-supported AIDS Clinical Trials Group (ACTG).
Awardees
- Dr. John Eldridge, Wyeth Vaccine Research, "HIV Expression Plasmids and Molecular Adjuvants"
- Dr. Chang Yi Wang, United Biomedical, Inc., "Synthetic CD4 Targeted Therapeutic Vaccine"
- Dr. Charles Nicolette, Argos Therapeutics, Inc., "Antigen Message Pulsed Autologous Dendritic Cell Therapies"
back to top